

U.S. Patent Application Serial No. 10/594,449

Response filed December 17, 2008

Reply to OÁ dated August 19, 2008

AMENDMENTS TO THE CLAIMS:

Please amend claims 1 and 2, as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently amended): A recombinant herpesvirus that is not infectious laryngotracheitis virus, wherein the recombinant herpesvirus has a DNA that encodes the polypeptide of SEQ ID NO: 2, ~~or encodes a modification of SEQ ID NO: 2 in which from one to seven amino acids have been deleted, added, or substituted,~~ but that does not encode any other portion of the gB gene of infectious laryngotracheitis virus.

Claim 2 (Currently amended): The recombinant herpesvirus according to claim 1 in which a DNA encoding the amino acid sequence set forth in SEQ ID NO: 4 ~~or a modification of SEQ ID NO: 4 in which from one to seven amino acids have been deleted, added or substituted,~~ is linked in a frame with the 3'-end of the DNA encoding the polypeptide of SEQ ID NO: 2 ~~or the modification of SEQ ID NO: 2.~~

Claim 3 (Previously presented): A recombinant herpesvirus according to claim 2, wherein the herpesvirus is a herpesvirus that infects avians.

U.S. Patent Application Serial No. **10/594,449**
Response filed December 17, 2008
Reply to OA dated August 19, 2008

Claim 4 (Previously presented): The recombinant herpesvirus according to claim 3 wherein the herpesvirus is Marek's disease virus type 1, 2 or 3.

Claim 5 (Previously presented): A vaccine against infectious laryngotracheitis virus comprising as an active ingredient a recombinant herpesvirus according to claim 4.

Claim 6 (Previously presented): The recombinant herpesvirus according to claim 1, wherein the herpesvirus is a herpesvirus that infects avians.

Claim 7 (Previously presented): The recombinant herpesvirus according to claim 6 wherein the herpesvirus is Marek's disease virus type 1, 2 or 3.

Claim 8 (Previously presented): A vaccine against infectious laryngotracheitis virus comprising as an active ingredient a recombinant herpesvirus according to claim 7.

Claim 9 (Previously presented): A vaccine against infectious laryngotracheitis virus comprising as an active ingredient a recombinant herpesvirus according to claim 6.

Claim 10 (Previously presented): A vaccine against infectious laryngotracheitis virus comprising as an active ingredient a recombinant herpesvirus according to claim 1.

U.S. Patent Application Serial No. 10/594,449
Response filed December 17, 2008
Reply to OA dated August 19, 2008

Claim 11 (Previously presented): A vaccine against infectious laryngotracheitis virus comprising as an active ingredient a recombinant herpesvirus according to claim 2.

Claim 12 (Previously presented): A vaccine against infectious laryngotracheitis virus comprising as an active ingredient a recombinant herpesvirus according to claim 3.